Linda Adams
Nurse Practitioner · Bixby, OKNPI 1578907101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,790, 3.2 times the $1,190 reported in 2021. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $48.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Johnson & Johnson$2K
- Alpha Cognition USA, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$733
- Otsuka America Pharmaceutical, Inc.$592
- plus $2K from 8 others
What the payments were for
- Food & beverage$9,66497%
- Education$2703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 55 | $2,050 |
| Johnson & Johnson | 38 | $1,917 |
| Alpha Cognition USA, Inc. | 17 | $1,850 |
| Teva Pharmaceuticals USA, Inc. | 14 | $1,156 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $733 |
| Otsuka America Pharmaceutical, Inc. | 13 | $592 |
| Alkermes, Inc. | 9 | $550 |
| Indivior Inc. | 25 | $337 |
| AbbVie | 3 | $250 |
| Pear Therapeutics (US), Inc. | 4 | $187 |
| Lundbeck LLC | 7 | $132 |
| Sumitomo Pharma America, Inc. | 5 | $89 |
| Harmony Biosciences LLC | 4 | $75 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zunveyl$4,156
- INVEGA SUSTENNA$1,302
- LYBALVI$1,243
- INGREZZA$1,089
- INVEGA TRINZA$789
- CAPLYTA$476
- Austedo XR$468
- AUSTEDO$236
- VRAYLAR$232
- REXULTI$230
- UZEDY$117
- ABILIFY MAINTENA$111
- RESET-O$108
How this compares
$9,934 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 56 | $218,663 |
| IngrezzaValbenazine Tosylate | 25 | $147,694 |
| Invega SustennaPaliperidone Palmitate | 31 | $108,484 |
| NuedextaDextromethorphan Hbr/Quinidine | 125 | $95,621 |
| PerserisRisperidone | 15 | $46,001 |
| Abilify MaintenaAripiprazole | 12 | $35,148 |
| RexultiBrexpiprazole | 16 | $11,331 |
| Duloxetine Hcl | 272 | $7,184 |
| Memantine Hcl | 212 | $7,026 |
| Trazodone Hcl | 424 | $5,824 |
| Sertraline Hcl | 347 | $5,776 |
| GemtesaVibegron | 21 | $5,117 |
| Buspirone Hcl | 111 | $2,675 |
| Aripiprazole | 55 | $2,027 |
| Fluvoxamine Maleate | 40 | $1,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,156 | $218,66356 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,050 | $147,69425 claims |
| Johnson & JohnsonInvega Sustenna | $1,917 | $108,48431 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $592 | $46,47928 claims |
| Indivior Inc.Perseris | $337 | $46,00115 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $89 | $5,11721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Bixby
- Jenny GuthrieTulsa$106K
- Leah MeltonNorman$87K
- Sara GoreOklahoma City$52K
- Teisha GalleglyMoore$43K
- Stacy NewberryTulsa$28K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Monica LawsonNorman$15K
- Amanda SmallTulsa$14K
- Janelle WagnerOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.